Delayed Onset of Cardiac Allograft Vasculopathy by Induction Therapy Using Anti-thymocyte Globulin

Our study suggests the long-term advantage of ATG in prevention of cardiac allograft vasculopathy. In contrast, OKT3 failed to show such benefit. However, induction therapy with either ATG or OKT3 did not exhibit a significant beneficial effect on long-term patient survival.